Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ArcticZymes Technologies ASA ( (DE:B4V) ) has issued an announcement.
ArcticZymes Technologies ASA, in collaboration with the Austrian Centre of Industrial Biotechnology, has extended their research partnership to enhance purification methods for bionanoparticles, crucial for gene therapies, vaccines, and cancer treatments. This collaboration aims to improve the efficiency, scalability, and cost-effectiveness of BNP-based therapeutics, leveraging ArcticZymes’ SAN family enzymes and receiving additional funding from the COMET program. The partnership highlights ArcticZymes’ commitment to innovation and practical solutions in bioprocessing, with implications for advancing biomanufacturing workflows and training future talent.
More about ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing, and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD), and biomanufacturing. Its headquarters are based in Tromsø, Norway, at the SIVA Science Park. ArcticZymes Technologies’ IP and capabilities are protected via a large portfolio of patents.
Average Trading Volume: 49,834
Current Market Cap: NOK827.4M
Find detailed analytics on B4V stock on TipRanks’ Stock Analysis page.